Related Experiment Videos
Refining treatment approaches in obsessive-compulsive disorder
1Department of Psychiatry, St. Mary's Hospital Medical School, London, England, UK.
International Clinical Psychopharmacology
|December 1, 1996
Summary
Selective serotonin reuptake inhibitors (SSRIs) and clomipramine are equally effective for managing obsessive-compulsive disorder (OCD). SSRIs offer better tolerability, improving long-term treatment outcomes for OCD patients.
Area of Science:
- Psychiatry
- Pharmacology
- Neuroscience
Background:
- Obsessive-compulsive disorder (OCD) is a common psychiatric condition requiring effective management.
- Historically, OCD was considered treatment-resistant, with effective therapies emerging only in the last 15 years.
- Clomipramine's efficacy in OCD, linked to serotonin reuptake inhibition, marked a therapeutic advance.
Purpose of the Study:
- To review the pharmacological management of OCD.
- To compare the efficacy and tolerability of clomipramine and selective serotonin reuptake inhibitors (SSRIs).
- To assess the impact of side effects on treatment outcomes in OCD.
Main Methods:
- Review of existing literature and meta-analyses comparing clomipramine and SSRIs for OCD treatment.
- Examination of direct comparative studies between clomipramine and SSRIs.
- Analysis of side effect profiles and their influence on long-term treatment adherence and efficacy.
Main Results:
- Initial meta-analyses suggested clomipramine was more effective than SSRIs for OCD.
- Direct comparisons indicate clomipramine and SSRIs have comparable efficacy.
- SSRIs demonstrate better tolerability than clomipramine, crucial for long-term OCD management.
Conclusions:
- Both clomipramine and SSRIs are effective pharmacological treatments for OCD.
- SSRIs are generally better tolerated than clomipramine.
- Improved tolerability of SSRIs may lead to more favorable long-term treatment outcomes for OCD patients.